These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37290665)

  • 1. Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.
    Tang Y; Sang H
    ESC Heart Fail; 2023 Aug; 10(4):2524-2533. PubMed ID: 37290665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
    Tang Y; Sang H
    Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial.
    Lin L; Xiu QP; Liu F; Zhang HJ; Chen YF
    Cardiovasc Drugs Ther; 2023 Dec; ():. PubMed ID: 38095763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
    Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
    ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
    Davis JA; Booth D; McEwan P; Solomon SD; McMurray JJV; de Boer RA; Comin-Colet J; Bachus E; Chen J
    Eur J Heart Fail; 2024 Mar; 26(3):664-673. PubMed ID: 38509642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial.
    Booth D; Davis JA; McEwan P; Solomon SD; McMurray JJV; De Boer RA; Comin-Colet J; Bachus E; Chen J
    Eur J Heart Fail; 2023 Aug; 25(8):1386-1395. PubMed ID: 37344985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
    Rane A; Nechi RN; Imam M; Zoni CR; Ndikumukiza C; Karaye IM; Yunusa I; Alanzi A
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1045-1053. PubMed ID: 37610112
    [No Abstract]   [Full Text] [Related]  

  • 9. SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study.
    Lu H; Shang P; Zhou D
    Front Pharmacol; 2023; 14():1155210. PubMed ID: 37771722
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
    Krittayaphong R; Permsuwan U
    Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
    Liao CT; Yang CT; Toh HS; Chang WT; Chang HY; Kuo FH; Lee MC; Hua YM; Tang HJ; Strong C; Ou HT
    Cardiovasc Diabetol; 2021 Oct; 20(1):204. PubMed ID: 34627231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
    Bhatt AS; Vaduganathan M; Claggett BL; Kulac IJ; Anand IS; Desai AS; Fang JC; Hernandez AF; Jhund PS; Kosiborod MN; Sabatine MS; Shah SJ; Vardeny O; McMurray JJV; Solomon SD; Gaziano TA
    J Am Heart Assoc; 2024 Mar; 13(5):e032279. PubMed ID: 38390793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
    Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS
    JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
    Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
    Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
    Parizo JT; Goldhaber-Fiebert JD; Salomon JA; Khush KK; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Cardiol; 2021 Aug; 6(8):926-935. PubMed ID: 34037681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
    Dixit NM; Truong KP; Vaduganathan M; Ziaeian B; Fonarow GC
    JACC Heart Fail; 2024 Jul; 12(7):1226-1237. PubMed ID: 38703159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt.
    Abdelhamid M; Elsisi GH; Seyam A; Shafie A; Kirollos M; Emad S; Mansy S; Sobhy M
    J Med Econ; 2022; 25(1):450-456. PubMed ID: 35291896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China.
    Jiang Y; Zheng R; Sang H
    Front Pharmacol; 2021; 12():733681. PubMed ID: 34858172
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China.
    Jiang Y; Xie J
    Front Cardiovasc Med; 2022; 9():946399. PubMed ID: 36119747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.